SS
LYRA

Steve Schonfeld’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Steve Schonfeld’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,146
Closed -$2.22M – 2397
2024
Q1 		$2.22M Buy
7,146
+6,312
+757% +$1.68M 0.01% 958
2023
Q4 		$219K Buy
+834
New +$151K ﹤0.01% 1513

Other funds holding LYRA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's LYRA Position: Q2 2024 in Review

Steve Schonfeld sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2024, closing a stake of 7,146 shares — an estimated $2.22M sold.

Steve Schonfeld first reported a position in LYRA in Q4 2023 and held it in 2 quarters. The position peaked at $2.22M in Q1 2024. 51 funds tracked by Wall St. Rank hold LYRA as of Q2 2024.

  • Steve Schonfeld reported no remaining LYRA THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Steve Schonfeld sold 7,146 LYRA THERAPEUTICS INC shares in Q2 2024, an estimated $2.22M.
  • Steve Schonfeld first reported a position in LYRA THERAPEUTICS INC in Q4 2023 and held it in 2 quarters.
  • Steve Schonfeld's LYRA THERAPEUTICS INC position peaked at $2.22M in Q1 2024.
  • 51 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.